Ac­celeron's PAH drug gets the FDA's red car­pet treat­ment with break­through sta­tus

Days af­ter scor­ing ex­pand­ed ap­proval for its po­ten­tial block­buster ane­mia ther­a­py, Ac­celeron has the FDA fawn­ing over its ex­per­i­men­tal drug so­tater­cept — with the US reg­u­la­tor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER